Sanofi is halting the phase 3 MOBILIZE trial evaluating riliprubart for chronic inflammatory demyelinating polyneuropathy due to lack of efficacy.
Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company's ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
Dianthus Therapeutics (DNTH) stock slides as Sanofi (SNY) halts a late-stage trial for a drug similar to U.S. biotech's lead ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results